ResearcherCentre National de la Recherche ScientifiqueNo recent work listed

Andrei Maksimenko

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0140-9759; OpenAlex author ID A5103010747. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2015: 2 papers

Papers 2

Lipid-Conjugation of Endogenous Neuropeptides: Improved Biotherapy against Human Pancreatic Cancer. Co-author DOI 10.1002/adhm.201400816 ↗
Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies. Co-author DOI 10.1016/j.ijpharm.2014.11.009 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Patrick Couvreur · 2 shared papers, 2015 · strength 0.12
- Paper Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies. DOI 10.1016/j.ijpharm.2014.11.009 ↗
- Paper Lipid-Conjugation of Endogenous Neuropeptides: Improved Biotherapy against Human Pancreatic Cancer. DOI 10.1002/adhm.201400816 ↗
Gopakumar Gopalakrishnan · 1 shared paper, 2015 · strength 0.06
- Paper Lipid-Conjugation of Endogenous Neuropeptides: Improved Biotherapy against Human Pancreatic Cancer. DOI 10.1002/adhm.201400816 ↗
Simona Mura · 1 shared paper, 2015 · strength 0.06
- Paper Lipid-Conjugation of Endogenous Neuropeptides: Improved Biotherapy against Human Pancreatic Cancer. DOI 10.1002/adhm.201400816 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.